Skip to main content

Table 2 Comparison of median and interquartile range of plasma efavirenz (EFV) concentrations (mg/L) between HIV patients receiving EFV based HAART only and TB-HIV coinfected patients receiving EFV based HAART with rifampicin (RIF) based TB therapy

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

  

Treatment group

p

 

EFV only

 

EFV + RIF

N

Median (IQR)

N

Median (IQR)

Day-3

57

2.48 (1.85-2.92)

107

1.85 (1.34-2.86)

0.02

week-1

53

2.37 (1.92-3.18)

57

1.80 (1.34-2.49)

0.01

week-2

53

2.21 (1.63-3.21)

100

1.94 (1.38-2.60)

0.21

week-4

49

2.45 (1.73-3.22)

103

1.87 (1.43-3.13)

0.48

week-6

38

2.37 (1.70-3.51)

86

1.89 (1.63-4.19)

0.93

week-8

50

2.41 (1.64-3.06)

118

1.82 (1.42-3.21)

0.40

week-12

44

2.41 (1.65-3.55)

101

2.04 (1.47-3.64)

0.69

  1. Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7, 8 and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log transformed efavirenz concentration was used using independent sample T-test.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us